ABOUT US

    Wayshine (Hangzhou) Biopharm Co., Ltd. (hereinafter referred to as "Wayshine Biopharm"), founded in 2016, is the domestic parent company of a multinational pharmaceutical R&D group, with its China headquarters located in Shanghai. Deeply engaged in the biopharm field, the Company focuses on the independent R&D of innovative anti-tumor drugs. Its core therapeutic areas cover major diseases including lung cancer, glioma, breast cancer, ovarian cancer, and pancreatic cancer, and the Company is committed to providing innovative medical solutions to cancer patients worldwide.

    R&D capability is the core competitiveness of Wayshine Biopharm. Adhering to the R&D philosophy of "Follow the Science, Pursue Innovation," the Company focuses on small-molecule targeted therapies for brain tumors that address unmet clinical needs. It has established a technology platform enabling efficient penetration of therapeutics across the blood-brain barrier and formed a comprehensive R&D system spanning target discovery, target validation, compound design, and preclinical development, while collaborating with renowned domestic and international CRO organizations to efficiently advance drug development. The Company's lead product, WSD0922, is a first-in-class blood-brain barrier-penetrating EGFR/EGFRvIII-targeted inhibitor for indications including non-small cell lung cancer and glioma. It obtained IND clearance from the U.S. Food and Drug Administration (FDA) in 2019 and is being evaluated in Phase I/II clinical trials in the United States in collaboration with Mayo Clinic, a world-leading medical institution. In 2024, the Company initiated a domestic clinical trial in non-small cell lung cancer patients harboring the C797S resistance mutation following first-line treatment with third-generation EGFR inhibitors; the trial has now progressed to Phase III and been granted Breakthrough Therapy Designation (BTD) by the NMPA.

    In addition, the Company has built a strategic R&D pipeline: WSD0628, an ATM-targeted inhibitor, has successively received FDA Orphan Drug Designation and U.S. IND clearance and is currently in a Phase I clinical trial in the United States; WSD1227, a brain-penetrant anti-angiogenic agent, is currently in the preclinical IND-enabling stage.

    The Company was founded by Dr. Zhong Wei, an overseas-returned scientist with more than 20 years of experience in the development of novel drug molecules and a leading figure in brain-penetrant drug discovery. Dr. Zhong previously served at AstraZeneca's global new drug R&D center, where the project he led on HER2-positive breast cancer with brain metastases was honored with AstraZeneca's "Star of Science" Award. Of the molecules he personally developed, one has entered Phase III, three have entered Phase II, and one has entered Phase I clinical trials, demonstrating favorable safety and efficacy profiles.